Key facts
- Notable investors include Connecticut Innovations, Venture Center, National Center For Advancing Translational Sciences, Qualifying Therapeutic Discovery Project, University of Connecticut Technology Incubation Program.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cheminpharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Cheminpharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cheminpharma
Developer of a biotechnology platform intended to provide a full spectrum of preclinical drug discovery services. The company's platform specializes in drug design, computational chemistry, medicinal chemistry, organic synthesis and biochemistry, enabling clients to access effective drugs and compounds for the unmet medical needs.
- Sector
- Healthcare
- HQ
- Hamden, CT, United States
- Founded
- 2007
- Employees
- 3
- Website
- cheminpharma.com/
- Ownership
- Privately Held (backing)
Cheminpharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cheminpharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cheminpharma in its N-PORT filings yet. We sweep new filings monthly.